CIP
MYGN icon

Cornerstone Investment Partners’s Myriad Genetics MYGN Stock Holding History

Cornerstone Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,695
Closed -$176K – 317
2025
Q4 		$176K Buy
28,695
+18
+0.1% +$131 0.01% 192
2025
Q3 		$207K Buy
+28,677
New +$170K 0.01% 157

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cornerstone Investment Partners's MYGN Position: Q1 2026 in Review

Cornerstone Investment Partners sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 28,695 shares — an estimated $176K sold.

Cornerstone Investment Partners first reported a position in MYGN in Q3 2025 and held it in 2 quarters. The position peaked at $207K in Q3 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Cornerstone Investment Partners reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Cornerstone Investment Partners sold 28,695 Myriad Genetics shares in Q1 2026, an estimated $176K.
  • Cornerstone Investment Partners first reported a position in Myriad Genetics in Q3 2025 and held it in 2 quarters.
  • Cornerstone Investment Partners's Myriad Genetics position peaked at $207K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Cornerstone Investment Partners's 13F filing for Q1 2026, filed 8 May 2026.